Key Takeaways Bristol Myers and BioNTech's pumitamig plus chemo showed a 76.3% response rate in ES-SCLC.The phase II trial data supported dose selection for the pivotal ROSETTA LUNG-01 study.Pumitamig received FDA Orphan Drug status for small cell lung cancer treatment in 2025.Bristol Myers ((BMY) and partner BioNTech ((BNTX) recently presented interim data from a global randomized mid-stage study evaluating pumitamig plus chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC). Pumit ...

据卢特尼克表示，总统特朗普正在调动多个行政部门机构以实现这一目标。"我刚刚接到(卫生部长)博 比·肯尼迪的电话。我还接到了(美国医疗保险和医疗补助服务中心主任)梅赫迈特·奥兹的电话，他们都 和我说，'好吧，让我们开始推进这件事吧'。"卢特尼克在采访中补充说。 总部位于美国的吉利德(GILD.US)、百时美施贵宝(BMY.US)、强生(JNJ.US)、再生元(REGN.US)、安进 (AMGN.US)以及艾伯维(ABBV.US)，还包括总部位于欧洲的大型药企默克集团(Merck KGaA)、赛诺菲 (SNY.US)、葛兰素史克(GSK.US)、阿斯利康(AZN.US)、诺和诺德(NVO.US)、罗氏(RHHBY.US)以及诺 华(NVS.US)也收到了特朗普的来信。 "总统将会说，大型药品制造商们如果不在那边以更高的价格进行出售，就不能在这里销售。别再愿意 以那么低的价格卖给他们了。"卢特尼克在采访中表示。特朗普给药企们设定遵守该最惠国政策的最后 期限为9月29日，并且他在此之前作出了上述的坚定表态。 智通财经APP获悉，美国商务部长霍华德·卢特尼克近日在接受媒体采访时表示，总统唐纳德·特朗普正 在联合多个联邦 ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best inexpensive stocks to buy according to hedge funds. On September 8, BioNTech (NASDAQ:BNTX) and Bristol Myers Squibb presented positive interim data from a global randomized Phase 2 trial of their investigational bispecific antibody, pumitamig (BNT327/BMS986545). The trial evaluated pumitamig in combination with chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC). The data, consistent with a prior Phase 2 trial in China, ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best growth stocks under $50 to buy now. On September 8, BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb Company (NYSE:BMY), retaining the price target of $47.00. Why Investors View Bristol‑Myers Squibb (BMY) as a Safe Dividend Stock for Income The analyst attributed the rating to the performance of Cobenfy, the company’s new product, in the market, stating that its growth has been stable with a modest percentage in ...

Key Takeaways Bristol Myers shares fell 19.2% in six months, lagging industry, sector, and the S&P 500 Index.Legacy drugs face steep generic pressure, but Eliquis and Revlimid offer partial top-line support.Growth portfolio drugs like Opdivo, Reblozyl, Breyanzi, and Camzyos drive strong sales momentum.The going remains rough for Bristol Myers ((BMY). Shares of this biotech giant have lost 19.2% in the past six months against the industry’s growth of 0.6%. The stock has also underperformed the sector and the ...

Bristol-Myers Squibb Company (NYSE:BMY) is among the undervalued wide moat stocks to buy now. Flputnam Investment Management Co. has raised its position in Bristol-Myers Squibb Company (NYSE:BMY) by 52.4% in the first quarter, according to the recent disclosure with the Securities and Exchange Commission (SEC). After acquiring 76,321 shares, the financial services firm now owns 222,079 shares of the company’s stock, valued at $13,545,000. From an attractive 5.23% forward annual dividend yield to strong ca ...

临床试验数据 - BioNTech与百时美施贵宝联合公布pumitamig（BNT327/BMS986545）联合化疗治疗未经治疗的广泛期小细胞肺癌的2期中期数据 在38名可评估患者中达到76.3%的确认总缓解率（20mg/kg剂量组85% 30mg/kg剂量组66.7%）和100%的疾病控制率 平均肿瘤缩小56.7%且近90%患者显示早期肿瘤缩小 [1] - 中位无进展生存期为6.8个月 总生存期数据尚未成熟 [2] - 安全性特征可控且无新警示信号 ≥3级pumitamig相关不良事件在低剂量组发生1例 高剂量组发生5例 [3] 研发进展 - 三期临床试验ROSETTA-LUNG-01正在进行 比较pumitamig联合化疗与atezolizumab联合化疗用于一线ES-SCLC治疗的疗效 [3] 市场表现 - BioNTech股价下跌8.16%至103.28美元 百时美施贵宝股价下跌1.67%至46.36美元 [3]

PresentationTerence FlynnEquity Analyst All right. Thanks. I think we're going to get started. But I'm Terence Flynn, Morgan Stanley's U.S. biopharma analyst. I'm very pleased to be hosting Bristol-Myers this morning. Joining us from the company, we have Chris Boerner, the company's CEO; and Adam Lenkowsky, the company's Chief Commercial Officer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, pleas ...

to the latest now out of Washington. The Trump administration's immigration rate of a Hyundai facility in Georgia raising fresh concerns for businesses when it comes to the labor force. Megan Cassella in Washington with the latest.Megan, hey guys, good morning. So, this is a prime example here of competing priorities within the Trump administration. This one showing how the president's goals of a massive expansion of foreign investment and US manufacturing could be at odds with his desired crackdown on ille ...

A next-generation cancer immunotherapy by BioNTech and partner Bristol Myers Squibb led to encouraging tumour shrinkage in a mid-stage trial on small cell lung cancer that has started spreading, the German biotech firm said on Monday. ...